A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom

References

• Troeger C, Blacker B, Khalil IA, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Infect Dis. 2018;18(11):1191–1210. doi: 10.1016/S1473-3099(18)30310-4
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. 2019. [cited 2022 December 02]. Available from: https://www.who.int/publications/i/item/10665-310968
   Google Scholar
• UK Health Security Agency. Pneumococcal: the Green Book, chapter 25. 2020 [cited2022 August 01]. Available from: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25
   Google Scholar
• Sharp A, Minaji M, Panagiotopoulos N, et al. Estimating the burden of adult hospital admissions due to RSV and other respiratory pathogens in England. Influenza Other Respir Viruses. 2022 Jan;16(1):125–131. doi: 10.1111/irv.12910
   PubMed Web of Science ®Google Scholar
• Trotter CL, Stuart JM, George R, et al. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis. 2008 May;14(5):727–733. doi: 10.3201/eid1405.071011
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012 Jul;65(1):17–24. doi: 10.1016/j.jinf.2012.02.017
   PubMed Web of Science ®Google Scholar
• Campling J, Jones D, Chalmers JD, et al. The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England. Pneumonia (Nathan). 2019;11(1):4. doi: 10.1186/s41479-019-0063-z
   PubMedGoogle Scholar
• Campling J, Jones D, Chalmers J, et al. Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England. BMJ Open Respir Res. 2020 Oct;7(1):e000703. doi: 10.1136/bmjresp-2020-000703.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Campling J, Dicker A, et al. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med. 2016 May 11;16(1):77. doi: 10.1186/s12890-016-0242-0
   PubMedGoogle Scholar
• Chakrabarti B, Lane S, Jenks T, et al. Predictors of 30-day readmission following hospitalisation with community-acquired pneumonia. BMJ Open Respir Res. 2021 Mar;8(1):e000883. doi: 10.1136/bmjresp-2021-000883
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, van Hoek AJ, Fleming D, et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ. 2012 Oct 26;345(oct26 1):e6879. doi: 10.1136/bmj.e6879
   PubMedGoogle Scholar
• Chiavenna C, Presanis AM, Charlett A, et al. Estimating age-stratified influenza-associated invasive pneumococcal disease in England: a time-series model based on population surveillance data. PLOS Med. 2019;16(6):e1002829. doi: 10.1371/journal.pmed.1002829
   PubMed Web of Science ®Google Scholar
• Amin-Chowdhury Z, Aiano F, Mensah A, et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on invasive pneumococcal disease and risk of pneumococcal coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): prospective national cohort study, England. Clinl Infect Dis. 2020;72(5):e65–e75. doi: 10.1093/cid/ciaa1728
   Web of Science ®Google Scholar
• Ruuskanen O, Lahti E, Jennings LC, et al. Viral pneumonia. Lancet. 2011 Apr 9;377(9773):1264–1275. doi: 10.1016/S0140-6736(10)61459-6
   PubMed Web of Science ®Google Scholar
• Hyams C, Challen R, Begier E, et al. Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: a prospective cohort study. Lancet Reg Health Eur. 2022;21:100473. doi: 10.1016/j.lanepe.2022.100473
   PubMedGoogle Scholar
• Brendish NJ, Malachira AK, Beard KR, et al. Hospitalised adults with pneumonia are frequently misclassified as another diagnosis. Respir med. 2019 Apr;150:81–84.
   PubMed Web of Science ®Google Scholar
• Hyams C, Amin-Chowdhury Z, Fry NK, et al. Streptococcus pneumoniae septic arthritis in adults in Bristol and bath, United Kingdom, 2006-2018: a 13-year retrospective observational cohort study. Emerg Microbes Infect. 2021 Dec;10(1):1369–1377. doi: 10.1080/22221751.2021.1945955
   PubMed Web of Science ®Google Scholar
• Myint PK, Hawkins KR, Clark AB, et al. Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort. Epidemiol Infect. 2016 Mar;144(4):803–809. doi: 10.1017/S0950268815001971
   PubMed Web of Science ®Google Scholar
• Lopez A, Mariette X, Bachelez H, et al. Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun. 2017 Jun;80:10–27.
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ, Pebody R, et al. The current burden of pneumococcal disease in England and Wales. J Infect. 2006 Jan;52(1):37–48. doi: 10.1016/j.jinf.2005.02.008
   PubMed Web of Science ®Google Scholar
• Patterson L, Irvine N, Wilson A, et al. Outbreak of invasive pneumococcal disease at a Belfast shipyard in men exposed to welding fumes, Northern Ireland, April–May 2015: preliminary report. Euro Surveill. 2015;20(21):21138. doi: 10.2807/1560-7917.ES2015.20.21.21138
   PubMedGoogle Scholar
• emc. APEXXNAR suspension for injection in pre-filled syringe. 2022 [cited 2022 August18]. Available from: https://www.medicines.org.uk/emc/product/13461/smpc#gref
   Google Scholar
• Joint Committee on Vaccination and Immunisation. Minute of the meeting held on 07 June 2023. 2023 [cited 2023 August 08]. Available from: https://app.box.com/s/iddfb4ppwkmtjusir2tc/file/1262409204637
   Google Scholar
• emc. Vaxneuvance. 2023 [cited 2023 September 11]. Available from: https://www.medicines.org.uk/emc/product/13754/smpc
   Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–543. doi: 10.1016/S1473-3099(15)70044-7
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018 Apr;18(4):441–451. doi: 10.1016/S1473-3099(18)30052-5
   PubMed Web of Science ®Google Scholar
• Jochems SP, Weiser JN, Malley R, et al. The immunological mechanisms that control pneumococcal carriage. PLOS Pathog. 2017 Dec;13(12):e1006665. doi: 10.1371/journal.ppat.1006665
   PubMed Web of Science ®Google Scholar
• Davies LRL, Cizmeci D, Guo W, et al. Polysaccharide and conjugate vaccines to Streptococcus pneumoniae generate distinct humoral responses. Sci Transl Med. 2022 Aug 3;14(656):eabm4065. doi: 10.1126/scitranslmed.abm4065
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021 Feb;21(2):83–100. doi: 10.1038/s41577-020-00479-7
   PubMed Web of Science ®Google Scholar
• Micoli F, Romano MR, Carboni F, et al. Strengths and weaknesses of pneumococcal conjugate vaccines. Glycoconj J. 2023 Apr;40(2):135–148. doi: 10.1007/s10719-023-10100-3
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 Mar 19;372(12):1114–1125. doi: 10.1056/NEJMoa1408544
   PubMed Web of Science ®Google Scholar
• Mendes D, Averin A, Atwood M, et al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res. 2022 Dec;22(8):1285–1295. doi: 10.1080/14737167.2022.2134120
   PubMed Web of Science ®Google Scholar
• Lagousi T, Basdeki P, Routsias J, et al. Novel protein-based pneumococcal vaccines: assessing the use of distinct protein fragments instead of full-length proteins as vaccine antigens. Vaccines (Basel). 2019 Jan 19;7(1):9. doi: 10.3390/vaccines7010009
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Pneumococcal whole-cell and protein-based vaccines: changing the paradigm. Expert Rev Vaccines. 2017 Dec;16(12):1181–1190. doi: 10.1080/14760584.2017.1393335
   PubMed Web of Science ®Google Scholar
• Patterson S, Webber C, Michael P, et al. A post hoc assessment of duration of protection in CAPiTA (community acquired pneumonia immunization trial in adults). Trials Vaccinol. 2016;5:92–96. doi: 10.1016/j.trivac.2016.04.004
   Google Scholar
• Suaya JA, Jiang Q, Scott DA, et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. 2018 Mar 7;36(11):1477–1483. doi: 10.1016/j.vaccine.2018.01.049
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012 Nov 6;30(48):6802–6808. doi: 10.1016/j.vaccine.2012.09.019
   PubMed Web of Science ®Google Scholar
• Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018 Dec;6:42–50.
   PubMedGoogle Scholar
• Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLOS Med. 2020 Oct;17(10):e1003326. doi: 10.1371/journal.pmed.1003326
   PubMed Web of Science ®Google Scholar
• Tin Tin Htar M, Stuurman AL, Ferreira G, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017;12(5):e0177985. doi: 10.1371/journal.pone.0177985
   PubMed Web of Science ®Google Scholar
• Chandler T, Furmanek S, Carrico R, et al. 23-valent pneumococcal polysaccharide vaccination does not prevent community-acquired pneumonia hospitalizations due to vaccine-type streptococcus pneumoniae. Microorganisms. 2022 Mar 4;10(3):560. doi: 10.3390/microorganisms10030560
   PubMed Web of Science ®Google Scholar
• Vyse A, Campling J, Czudek C, et al. A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. Expert Rev Vaccines. 2021 Oct;20(10):1311–1325. doi: 10.1080/14760584.2021.1984888
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Miller E. Pneumococcal pneumonia. Thorax. 2020 Jan;75(1):6–7. doi: 10.1136/thoraxjnl-2019-214135
   PubMed Web of Science ®Google Scholar
• Amin-Chowdhury Z, Collins S, Sheppard C, et al. Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in England: a prospective observational cohort study, 2014-2018. Clin Infect Dis. 2020 Nov 5;71(8):e235–e243. doi: 10.1093/cid/ciaa043
   PubMed Web of Science ®Google Scholar
• Klugman KP, Rodgers GL. Time for a third-generation pneumococcal conjugate vaccine. Lancet Infect Dis. 2021;21(1):14–16. doi: 10.1016/S1473-3099(20)30513-2
   PubMed Web of Science ®Google Scholar
• Vyse A, Campling J, Czudek C, et al. The proportion of contemporary invasive pneumococcal disease and pneumococcal pneumonia in UK adults reflected by serotypes included in the 13-valent pneumococcal conjugate vaccine and next generation higher valency pneumococcal conjugate vaccines in development. Vaccine. 2020 Dec 3;38(51):8068–8070. doi: 10.1016/j.vaccine.2020.10.090
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov. A phase 1/phase 2 study of polyvalent pneumococcal conjugate vaccine (V116) in adults (V116-001). 2022 [cited 2022 August 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT04168190?cond=A+Phase+1%2FPhase+2%2C+Randomized%2C+Double-blind+Study+to+Evaluate+the+Safety%2C+Tolerability%2C+and+Immunogenicity+of+a+Polyvalent+Pneumococcal+Conjugate+Vaccine+in+Adults&draw=2&rank=1
   Google Scholar
• ClinicalTrial.gov. A single ascending dose study in adults (stage 1) and single ascending dose-finding study (stage 2) in elderly subjects with ASP3772, a pneumococcal vaccine. 2022 [cited 2022 August 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT03803202
   Google Scholar
• ClinicalTrial.gov. Safety, tolerability, and immunogenicity study of a 24-valent pneumococcal conjugate vaccine (VAX-24) in adults. 2022 [cited 2022 August 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT05266456?term=VAX-24&draw=2&rank=2
   Google Scholar
• Behrens C, Fairman J, Agarwal P, et al. Development of a next generation 30+ valent pneumococcal conjugate vaccine (VAX-XP) using site-specific carrier protein conjugation. Open Forum Infect Dis. 2021;8(Suppl 1):S615. doi: 10.1093/ofid/ofab466.1241
   Google Scholar
• Pick H, Daniel P, Rodrigo C, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18. Thorax. 2020 Jan;75(1):38–49. doi: 10.1136/thoraxjnl-2019-213725
   PubMed Web of Science ®Google Scholar
• Gessner BD, Jiang Q, Van Werkhoven CH, et al. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. Vaccine. 2019 Jul 9;37(30):4147–4154. doi: 10.1016/j.vaccine.2019.05.065
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Jiang Q, Gessner BD, et al. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: a systematic review and pooled analysis. Vaccine. 2019 Oct 8;37(43):6310–6316. doi: 10.1016/j.vaccine.2019.08.059
   PubMed Web of Science ®Google Scholar
• Sings HL, Gessner BD, Wasserman MD, et al. Pneumococcal conjugate vaccine impact on serotype 3: a review of surveillance data. Infect Dis Ther. 2021 Mar;10(1):521–539. doi: 10.1007/s40121-021-00406-w
   PubMed Web of Science ®Google Scholar
• Savulescu C, Krizova P, Valentiner-Branth P, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022 Jun 23;40(29):3963–3974. doi: 10.1016/j.vaccine.2022.05.011
   PubMed Web of Science ®Google Scholar
• Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013 Oct;57(7):952–962. doi: 10.1093/cid/cit428
   PubMed Web of Science ®Google Scholar
• Luck JN, Tettelin H, Orihuela CJ. Sugar-coated killer: serotype 3 pneumococcal disease. Front Cell Infect Microbiol. 2020;10:613287. doi: 10.3389/fcimb.2020.613287
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency. Pneumococcal polysaccharide vaccine (PPV) coverage report, England, April 2020 to March 2021. 2021 [cited 2022 July 29]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1035189/hpr1921-ppv-vc.pdf
   Google Scholar
• Thornhill J, Sivaramakrishnan A, Orkin C. Pneumococcal vaccination in people living with HIV. Vaccine. 2015 Jun 22;33(28):3159–3160. doi: 10.1016/j.vaccine.2014.07.086
   PubMed Web of Science ®Google Scholar
• Kirwan PD, Amin-Chowdhury Z, Croxford SE, et al. Invasive pneumococcal disease in people with human immunodeficiency virus in England, 1999-2017. Clin Infect Dis. 2021 Jul 1;73(1):91–100. doi: 10.1093/cid/ciaa522
   PubMed Web of Science ®Google Scholar
• Department of Health and Social Care and NHS England. NHS public health functions agreement 2019-20 - public health functions to be exercised by NHS England. 2019. [cited 2022 December 02]. Available from: https://www.gov.uk/government/publications/public-health-commissioning-in-the-nhs-2019-to-2020
   Google Scholar
• House of Commons Library. UK vaccination policy. 2022. [cited 2023 June 01]. Available from: https://researchbriefings.files.parliament.uk/documents/CBP-9076/CBP-9076.pdf
   Google Scholar
• Pebody RG, Hippisley-Cox J, Harcourt S, et al. Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999-2005. Epidemiol Infect. 2008 Mar;136(3):360–369. doi: 10.1017/S0950268807008436
   PubMed Web of Science ®Google Scholar
• Matthews I, Lu X, Xia Q, et al. Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis. BMC Public Health. 2020 Oct 21;20(1):1584. doi: 10.1186/s12889-020-09613-5
   PubMed Web of Science ®Google Scholar
• Sowden E, Mitchell WS. An audit of influenza and pneumococcal vaccination in rheumatology outpatients. BMC Musculoskelet Disord. 2007 Jul 4;8(1):58. doi: 10.1186/1471-2474-8-58
   PubMedGoogle Scholar
• McCarthy EM, de Barra E, Bergin C, et al. Influenza and pneumococcal vaccination and varicella status in inflammatory arthritis patients. Ir Med J. 2011 Jul;104(7):208–211.
   PubMedGoogle Scholar
• Hmamouchi I, Winthrop K, Launay O, et al. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 2015 Mar 17;33(12):1446–1452. doi: 10.1016/j.vaccine.2015.01.065
   PubMed Web of Science ®Google Scholar
• Costello R, Winthrop KL, Pye SR, et al. Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK: a retrospective cohort study using data from the clinical practice Research datalink. PLoS One. 2016;11(4):e0153848. doi: 10.1371/journal.pone.0153848
   PubMed Web of Science ®Google Scholar
• British HIV Association. British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015. 2015 [cited 2022 December 06]. Available from: https://www.bhiva.org/vaccination-guidelines
   Google Scholar
• Chadwick DR, Corbett K, Mann S, et al. Evaluation of a vaccine passport to improve vaccine coverage in people living with HIV. Int J STD AIDS. 2018 Oct;29(12):1190–1193. doi: 10.1177/0956462418779472
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143–1238. doi: 10.1016/j.bbmt.2009.06.019
   PubMed Web of Science ®Google Scholar
• Miller P, Patel SR, Skinner R, et al. Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the children’s cancer and Leukaemia group (CCLG), and British infection Association (BIA). J Infect. 2023 Jan;86(1):1–8. doi: 10.1016/j.jinf.2022.11.005
   PubMed Web of Science ®Google Scholar
• NHS Health Scotland. Interventions to engage people aged 60 years and over in influenza, shingles and pneumococcal immunisation programmes. 2020 [cited 2022 August 01]. Available from: http://www.healthscotland.scot/media/2962/interventions-to-engage-people-aged-60-years-and-over-in-immunisation-programmes-feb20.pdf
   Google Scholar
• National Institute for Health and Care Excellence. Vaccine uptake in the general population. 2022 [cited 2022 August 01]. Available from: www.nice.org.uk/guidance/ng218
   Google Scholar
• Wilmore SM, Philip KE, Cambiano V, et al. Influenza and pneumococcal vaccinations in dialysis patients in a London district general hospital. Clin Kidney J. 2014 Feb;7(1):27–32. doi: 10.1093/ckj/sft138
   PubMedGoogle Scholar
• Siriwardena AN, Rashid A, Johnson M, et al. Improving influenza and pneumococcal vaccination uptake in high-risk groups in Lincolnshire: a quality improvement report from a large rural county. Qual Primary Care. 2003;11:19–28.
   Google Scholar
• Myeloma UK. Vaccines and myeloma Infosheet. 2022 [cited 2023 February 14]. Available from: https://www.myeloma.org.uk/documents/vaccines-and-myeloma-infosheet/
   Google Scholar
• Cancer Research UK. Immunisations and cancer treatment. 2022 [cited 2022 December 09]. Available from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/immunisations-and-cancer-treatment
   Google Scholar
• Gallant AJ, Nicholls LAB, Rasmussen S, et al. Changes in attitudes to vaccination as a result of the COVID-19 pandemic: a longitudinal study of older adults in the UK. PLoS One. 2021;16(12):e0261844. doi: 10.1371/journal.pone.0261844
   PubMed Web of Science ®Google Scholar
• NHS England. Update on vaccination and immunisation changes for 2021/22. 2021 [cited 2022 December 09]. Available from: https://www.england.nhs.uk/publication/update-on-vaccination-and-immunisation-changes-for-2021-22/
   Google Scholar
• Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014 Mar;1(1):ofu024. doi: 10.1093/ofid/ofu024
   PubMedGoogle Scholar
• Pelton SI, Shea KM, Farkouh RA, et al. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis. 2015 Oct 30;15(1):470. doi: 10.1186/s12879-015-1162-y
   PubMedGoogle Scholar
• Bonnave C, Mertens D, Peetermans W, et al. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe. Eur J Clin Microbiol Infect Dis. 2019;38(4):785–791. doi: 10.1007/s10096-019-03485-3
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. The Pink Book. Chapter 17: pneumococcal disease. 2022 [cited 2022 July 28]. Available from: https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html#pneumococcal-vaccines
   Google Scholar
• Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. Adults: Updated recommendations of the advisory Committee on immunization practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:109–117. doi: 10.15585/mmwr.mm7104a1
   PubMed Web of Science ®Google Scholar
• Ministère des Affaires Sociales et de la Santé. Calendrier des vaccinations et recommandations vaccinales 2022. 2022 [cited 2022 August 01]. Available from: https://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_2022_mis_a_jour_juin_2022_v2.pdf
   Google Scholar
• STIKO. Recommendations by the Standing vaccination Committee (STIKO) at the Robert Koch Institute. 2023 [cited 2023 August 24]. Available from: https://www.rki.de/EN/Content/infections/Vaccination/recommandations/recommendations_node.html
   Google Scholar
• Government of Canada. Pneumococcal vaccine: Canadian immunization guide. 2023 [cited 2023 August 24]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html#a10
   Google Scholar
• Government of Canada. Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines. 2023 [cited 2023 June 01]. Available from: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines.html
   Google Scholar
• Australian Government. Pneumococcal disease. 2023 [cited 2023 August 24]. Available from: https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/pneumococcal-disease
   Google Scholar
• New Zealand Government. Immunisation Handbook 2020. Chapter 16: pneumococcal disease.2020 [cited 2022 August 05]. Available from: https://www.health.govt.nz/our-work/immunisation-handbook-2020/16-pneumococcal-disease
   Google Scholar
• European Centre for Disease Prevention and Control. Pneumococcal disease: recommended vaccinations. 2022 [cited 2022 July 28]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1
   Google Scholar
• Crooke SN, Ovsyannikova IG, Poland GA, et al. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16(1):25. doi: 10.1186/s12979-019-0164-9
   PubMed Web of Science ®Google Scholar
• Kuan V, Denaxas S, Gonzalez-Izquierdo A, et al. A chronological map of 308 physical and mental health conditions from 4 million individuals in the English national Health Service. Lancet Digital Health. 2019;1(2):e63–e77. doi: 10.1016/S2589-7500(19)30012-3
   PubMedGoogle Scholar
• Teh WH, Smith CJ, Barlas RS, et al. Impact of stroke-associated pneumonia on mortality, length of hospitalization, and functional outcome. Acta Neurol Scand. 2018 Oct;138(4):293–300. doi: 10.1111/ane.12956
   PubMed Web of Science ®Google Scholar
• Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir med. 2012 Aug;106(8):1124–1133. doi: 10.1016/j.rmed.2012.04.008
   PubMed Web of Science ®Google Scholar
• Zirk-Sadowski J, Masoli JA, Delgado J, et al. Proton-pump inhibitors and long-term risk of community-acquired pneumonia in older adults. J Am Geriatr Soc. 2018 Jul;66(7):1332–1338. doi: 10.1111/jgs.15385
   PubMed Web of Science ®Google Scholar
• Mooney JD, Imarhiagbe M, Ling J. Should UK pneumococcal vaccine eligibility criteria include alcohol dependency in areas with high alcohol-related mortality? Vaccines (Basel). 2018 May 2;6(2):25. doi: 10.3390/vaccines6020025
   PubMed Web of Science ®Google Scholar
• Baskaran V, Lim WS, McKeever TM. Effects of tobacco smoking on recurrent hospitalisation with pneumonia: a population-based cohort study. Thorax. 2022 Jan;77(1):82–85. doi: 10.1136/thoraxjnl-2020-216494
   PubMed Web of Science ®Google Scholar
• Millett ER, De Stavola BL, Quint JK, et al. Risk factors for hospital admission in the 28 days following a community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort study. BMJ Open. 2015 Dec 1;5(12):e008737. doi: 10.1136/bmjopen-2015-008737
   PubMed Web of Science ®Google Scholar
• Torén K, Blanc PD, Naidoo R, et al. Cumulative occupational exposure to inorganic dust and fumes and invasive pneumococcal disease with pneumonia. Int Arch Occup Environ Health. 2022 Oct;95(8):1797–1804. doi: 10.1007/s00420-022-01848-6
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease Active Bacterial Core Surveillance Team. N Engl J Med. 2000 Mar 9;342(10):681–689. doi: 10.1056/NEJM200003093421002
   PubMedGoogle Scholar
• McGeoch LJ, Ross S, Massa MS, et al. Cigarette smoking and risk of severe infectious respiratory diseases in UK adults: 12-year follow-up of UK biobank. J Public Health. 2023 Jun 22;fdad090. doi: 10.1093/pubmed/fdad090
   Google Scholar
• Miyashita L, Suri R, Dearing E, et al. E-cigarette vapour enhances pneumococcal adherence to airway epithelial cells. Eur Respir J. 2018 Feb;51(2):1701592. doi: 10.1183/13993003.01592-2017
   PubMed Web of Science ®Google Scholar
• Tyrrell G, Lee C, Eurich D. Is there a need for pneumococcal vaccination programs for the homeless to prevent invasive pneumococcal disease? Expert Rev Vaccines. 2021 Sep;20(9):1113–1121. doi: 10.1080/14760584.2021.1966301
   PubMed Web of Science ®Google Scholar
• Ly TDA, Perieres L, Hoang VT, et al. Pneumococcal infections and homelessness. J Prev Med Hyg. 2021 Dec;62(4):E950–E957. doi: 10.15167/2421-4248/jpmh2021.62.4.1805
   PubMedGoogle Scholar
• Lemay J-A, Ricketson LJ, Zwicker L, et al. Homelessness in adults with invasive pneumococcal disease in Calgary, Canada. Open Forum Infect Dis. 2019;6(10):ofz362. doi: 10.1093/ofid/ofz362
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Equality impact assessment. Pneumonia in children and adults: diagnosis and management. 2022 [cited 2023 August 01]. Available from: https://www.nice.org.uk/guidance/GID-NG10357/documents/equality-impact-assessment
   Google Scholar
• Thomas HL, Gajraj R, Slack MP, et al. An explosive outbreak of Streptococcus pneumoniae serotype-8 infection in a highly vaccinated residential care home, England, summer 2012. Epidemiol Infect. 2015 Jul;143(9):1957–1963. doi: 10.1017/S0950268814002490
   PubMed Web of Science ®Google Scholar
• Amin-Chowdhury Z, Iyanger N, Ramsay ME, et al. Outbreaks of severe pneumococcal disease in closed settings in the conjugate vaccines era, 2010–2018: a systematic review to inform national guidance in the UK. J Infect. 2019;79(6):495–502. doi: 10.1016/j.jinf.2019.10.009
   PubMed Web of Science ®Google Scholar
• Shields A, Faustini SE, Perez-Toledo M, et al. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. Thorax. 2020;75(12):1089–1094. doi: 10.1136/thoraxjnl-2020-215414
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: the SUMMIT trial. Respir med. 2017 Oct;131:27–34.
   PubMed Web of Science ®Google Scholar
• Szakmany T, Hollinghurst J, Pugh R, et al. Frailty assessed by administrative tools and mortality in patients with pneumonia admitted to the hospital and ICU in Wales. Sci Rep. 2021 Jun 28;11(1):13407. doi: 10.1038/s41598-021-92874-w
   PubMed Web of Science ®Google Scholar
• Ma HM, Yu RH, Woo J. Recurrent hospitalisation with pneumonia is associated with higher 1-year mortality in frail older people. Intern Med J. 2013 Nov;43(11):1210–1215. doi: 10.1111/imj.12258
   PubMed Web of Science ®Google Scholar
• Qcovid. Qcovid® risk calculator. 2022 [cited 2022 July 28]. Available from: https://qcovid.org/
   Google Scholar
• Bertran M, Amin-Chowdhury Z, Sheppard CL, et al. Increased incidence of invasive pneumococcal disease among children after COVID-19 pandemic, England. Emerg Infect Dis. 2022 Aug;28(8):1669–1672. doi: 10.3201/eid2808.220304
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency. Pneumococcal disease: cases caused by strains covered by Prevenar 13 vaccine. 2023 [cited 2023 June 01]. Available from: https://www.gov.uk/government/publications/pneumococcal-disease-cases-caused-by-strains-covered-by-prevenar-13-vaccine/pneumococcal-disease-cases-caused-by-strains-covered-by-prevenar-13-vaccine
   Google Scholar
• Perniciaro S, van der Linden M, Weinberger DM. Reemergence of invasive pneumococcal disease in Germany during the spring and summer of 2021. Clin Infect Dis. 2022 Feb 7;75(7):1149–1153. doi: 10.1093/cid/ciac100
   PubMed Web of Science ®Google Scholar
• Amin-Chowdhury Z, Bertran M, Sheppard CL, et al. Does the rise in seasonal respiratory viruses foreshadow the return of invasive pneumococcal disease this winter? Lancet Respir Med. 2022 Jan;10(1):e1–e2. doi: 10.1016/S2213-2600(21)00538-5
   PubMed Web of Science ®Google Scholar
• Campling J, Wright HF, Hall GC, et al. Hospitalization costs of adult community-acquired pneumonia in England. J Med Econ. 2022;25(1):912–918. doi: 10.1080/13696998.2022.2090734
   PubMed Web of Science ®Google Scholar
• Appleby J. NHS sickness absence during the COVID-19 pandemic. BMJ. 2021;372:n471. doi: 10.1136/bmj.n471
   PubMedGoogle Scholar
• Propper C, Stoye G, Zaranko B. The wider impacts of the coronavirus pandemic on the NHS. Fiscal Stud. 2020;41(2):345–356. doi: 10.1111/1475-5890.12227
   PubMed Web of Science ®Google Scholar
• Buchy P, Ascioglu S, Buisson Y, et al. Impact of vaccines on antimicrobial resistance. Int J Infect Dis. 2020 Jan;90:188–196.
   PubMed Web of Science ®Google Scholar
• Nowakowska M, van Staa T, Mölter A, et al. Antibiotic choice in UK general practice: rates and drivers of potentially inappropriate antibiotic prescribing. J Antimicrob Chemother. 2019;74(11):3371–3378. doi: 10.1093/jac/dkz345
   PubMed Web of Science ®Google Scholar
• Petersen I, Hayward AC. On behalf of the SACAR surveillance Subgroup. Antibacterial prescribing in primary care. J Antimicrob Chemother. 2007;60(Suppl 1):i43–i47. doi: 10.1093/jac/dkm156
   PubMedGoogle Scholar
• UK Health Security Agency. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR). 2022 [cited 2023 August 01]. Available from: https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report
   Google Scholar
• O’Neill J. Tackling globally: final report and recommendation. The review on antimicrobial resistance. 2016 [cited 2022 August 01]. Available from: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
   Google Scholar
• Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Nat Acad Sci. 2018;115(51):12896–12901. doi: 10.1073/pnas.1721095115
   PubMed Web of Science ®Google Scholar
• Burk M, El-Kersh K, Saad M, et al. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev. 2016 Jun;25(140):178–188. doi: 10.1183/16000617.0076-2015
   PubMed Web of Science ®Google Scholar
• Mitsi E, Reine J, Urban BC, et al. Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2. J Clin Invest. 2022 Apr 1;132(7):e157124. doi: 10.1172/JCI157124
   PubMed Web of Science ®Google Scholar
• Lewnard JA, Bruxvoort KJ, Fischer H, et al. Prevention of coronavirus disease 2019 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and severe acute respiratory syndrome coronavirus 2 in the respiratory tract. J Infect Dis. 2022 May 16;225(10):1710–1720. doi: 10.1093/infdis/jiab128
   PubMed Web of Science ®Google Scholar